Navigation Links
Results of the PEPCAD-DES trial reported at TCT 2011
Date:11/11/2011

ss or equal to 22 mm. Exclusion criteria were: acute myocardial infarction, chronic total occlusions, lesions in bypass grafts or bifurcations, multiple lesions in the target vessel, left main lesions, ISR in BMS, and/or contraindications for acetylsalicylic acid or clopidogrel.

The length of the balloon in both treatment groups was chosen to overlap the stenotic segment at least 2 mm at the proximal and distal margin. Dual antiplatelet therapy was prescribed for three months in both treatment groups. All patients were scheduled for control angiography at six months. Quantitative coronary analysis was performed in a blinded fashion relative to the treatment groups. The final angiographic follow-up was completed in September 2011.

The primary endpoint was six-month late lumen loss. In the POBA group, late lumen loss was 1.03 0.77; and in the DCB group, late lumen loss was 0.43 0.61. The rate of target lesion revascularization was 36.8% in the POBA group and 15.3% in the DCB group. The rate of major adverse cardiac events (MACE) was 50% in the POBA group and 16.7% in the DCB group.

"Results of this trial showed that for treatment of drug-eluting stent restenosis, a paclitaxel-coated balloon compared with a balloon angioplasty alone showed significantly lower late loss, a significantly lower binary restenosis rate, significantly less major adverse cardiac events, and no definite vessel thrombosis," said lead investigator Harald Rittger, MD from the University of Erlangen in Germany.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Results of the STACCATO Trial reported at TCT 2011
2. Results of the DEB-AMI Trial reported at TCT 2011
3. Results of the RIFLE STEACS clinical trial reported at TCT 2011
4. Results of the PARTNER Trial Cohort B 2-year follow up presented at TCT 2011
5. Results of the PARTNER Trial Cohort A cost effectiveness analysis reported
6. Combination epigenetic therapy clinical trial results
7. Results of the PARIS registry Reported at TCT 2011
8. Results of the TRIGGER-PCI trial reported at TCT 2011
9. Results of rapid gene trial reported at TCT 2011
10. Results of the BRIDGE trial reported at TCT 2011
11. First results of Angiomax (bivalirudin) vs. heparin in transcatheter aortic valve interventions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... York, New York (PRWEB) September 15, 2014 ... C.R. Bard, Inc. continue to move forward in the ... Southern District of West Virginia, Bernstein Liebhard LLP reports. ... issued a Final Order on September 10th that provides ... The Order notes that none of the affected plaintiffs ...
(Date:9/15/2014)... studies, approximately one out of every 40 individuals in the ... spinal muscular atrophy (SMA), a neurodegenerative disease that causes muscles ... Missouri have made a recent breakthrough with the development of ... models of the disease. In April, a patent was filed ... our lab is using to fight SMA is to ,repress ...
(Date:9/15/2014)... 2014 This year, Avenidas Village ... 2007. To mark the special occasion, Avenidas Village would ... village and helping it to get started seven years ... fun community for seniors. Members of Avenidas Village maintain ... in their own homes. They are able to have ...
(Date:9/15/2014)... Sept. 15, 2014 (HealthDay News) -- Births of multiple ... and death than singleton births, researchers report. The ... in vitro fertilization (IVF) could ease some of that ... have increased in tandem with births to older mothers ... from the University of New South Wales, Australia. ...
(Date:9/15/2014)... 2014 Providing additional expertise to ... LLP (“the Firm”) is proud to welcome ... with the Firm’s Litigation Support Services ... experience, Wolf will assist clients in litigation support, ... advisory matters. He will also provide guidance in ...
Breaking Medicine News(10 mins):Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:Researcher develops and proves effectiveness of new drug for spinal muscular atrophy 2Health News:Avenidas Village Celebrates Anniversary 2Health News:Study Ties Multiple Births to Higher Costs, Complications 2Health News:Study Ties Multiple Births to Higher Costs, Complications 3Health News:Cherry Bekaert Expands its Litigation Support Services Team Capabilities with the Addition of Steven Wolf 2Health News:Cherry Bekaert Expands its Litigation Support Services Team Capabilities with the Addition of Steven Wolf 3
... Over time, they boost risk for ulcers and even amputation, ... Something as simple as wearing the wrong size of shoes ... could lead to amputation, Scottish researchers say. , The study, ... diabetes patients, ages 24 to 89, who had their feet ...
... The use of a pedometer and a Web site that ... people with diabetes who participated in a recent walking study ... and VA Ann Arbor Healthcare System. The study also suggests ... others. , All participants in the study wore pedometers and ...
... most harmful strains of human papillomavirus is under study ... called nine-valent, is being compared with Gardasil, a quadrivalent ... two most deadly HPV types. , Were testing Gardasil ... Dr. Daron Ferris, family medicine physician and director of ...
... Researchers here have shown that in cell cultures, ... signals that stimulate certain tumor cells to grow and ... a way of slowing the progression and spread of ... have a better chance to work. , The ...
... Family Caregiver,s Month; Announces Availability ... More than 34 Million Caregivers, PALO ALTO, Calif., Nov. ... proud to support the more than 34 million,Americans caring for ... availability of its website. Designed to give caregivers the ...
... BAY, Wis., Nov. 19 Shopko announced today plans,to ... the fall of 2008. The,stores will be located in ... the continuation of an exciting growth,phase for Shopko," said ... Earlier this year Shopko broke ground on the first ...
Cached Medicine News:Health News:Ill-Fitting Shoes a Danger to Diabetics 2Health News:Pedometers motivate people with diabetes to walk more 2Health News:Pedometers motivate people with diabetes to walk more 3Health News:New HPV vaccine under study 2Health News:Stress hormone may hasten the progression of certain blood cancers 2Health News:Stress hormone may hasten the progression of certain blood cancers 3Health News:Resource to Help Care for Aging Parents Now Available Nationwide 2Health News:Resource to Help Care for Aging Parents Now Available Nationwide 3Health News:Shopko Announces Plans for Two New Stores 2
(Date:9/15/2014)... Sept. 15, 2014 PDL BioPharma, Inc. (PDL) (NASDAQ: ... paid the September 12, 2014, regular quarterly dividend payment of ... PDL as of September 5, 2014, the record date. ... manages a portfolio of patents and royalty assets, consisting ... and license agreements with various biotechnology and pharmaceutical companies. ...
(Date:9/15/2014)... Sept. 15, 2014 Research and Markets ... Drug Transfer Systems to 2020" report to their ... hazardous to humans has been receiving increasing amounts of ... substances become more clearly understood. For caregivers and their ... of attempts to mitigate exposure to cytotoxic drugs is ...
(Date:9/15/2014)... -- Research and Markets has announced the addition ... Tests, 9th Edition" report to their offering. ... testing market and all of its segments, providing customers with ... For Business Planning. This is the ninth edition ... 2013 and early 2014. New entrants, new technologies have entered ...
Breaking Medicine Technology:PDL BioPharma Completes Regular Quarterly Dividend Payment 2Closed Drug Transfer Systems to 2020 2Closed Drug Transfer Systems to 2020 3The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition 2The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition 3
... 17, 2011 Attorneys representing a group of U.S. citizens ... the drug thalidomide have filed a lawsuit in federal court ... show the drug was widely distributed in the United States. ... to respond to a number of Freedom of Information Act ...
... WASHINGTON, Nov. 17, 2011 The proliferation of brand ... generics to more expensive brands, will increase costs by ... employers, unions, and state employee plans, according to new ... Care Management Association (PCMA).   The use of these ...
Cached Medicine Technology:Hagens Berman: Patients Seek to Force FDA to Release Records Showing US Distribution of Thalidomide 2Hagens Berman: Patients Seek to Force FDA to Release Records Showing US Distribution of Thalidomide 3Brand Drug 'Copay Coupons' Undermine Generics, Raise Health Costs by $617 Million in Wisconsin 2
... is a threaded titanium anchor, ... procedures. The anchor features wide ... to optimize bone purchase, as ... to prevent suture binding. Fastin ...
The GII titanium anchor is the "Gold Standard" for soft tissue reattachment to bone. The GII's small size, high pull-out strength and wide range of clinical applications make it the anchor of choice ...
... 'proximal protection' -- providing complete protection from ... vessels with side branches. , ,Proxis ... does not require the attachment or exchange ... debris. ,Proxis is compatible with all ...
... System is the Fischer answer to cost ... specialist. The EP-X system is a highly ... dedicated EP lab system. Ease of access ... Pulsed Progressive Fluoroscopy (PPF) are but a ...
Medicine Products: